# Final blocker-resolution audit

## Role suite

- Total: 292
- Pass: 292
- Fail: 0
- Fixture failures: 0
- Obsolete expectation failures: 0
- Confirmed authorization failures: 0
- Confirmed workflow failures: 0

The suite now uses disposable deletion targets and `E2E ROLE FIXTURE` lab
references. It no longer relies on the historical deletion IDs or the old
`TESTPAID`/`TESTUNPAID` names. The final output is in
`phase6-role-final2.txt`.

## Reports

Fifteen temporary `E2E PAGINATION` visits were created, tested, and removed.
With rows per page set to 10, page 1 showed 10 records and page 2 showed 5.
Previous/Next changed the visible rows. Search and date filters remained in the
URL. The report table sort now toggles ascending and descending order and keeps
pagination usable. Empty state, page size controls, CSV export, and print
actions remain covered.

## Accounting decision

Supplier purchases are currently operational only: stock, gross amount,
discount, VAT, paid amount, and due amount are stored in `purchases`, while
supplier payments remain outside the journal model. The current ledger has cash
clearing, EVC clearing, revenue, and expense accounts, but no configured
Accounts Payable, Inventory Asset, or Purchases/COGS account model.

The recommended future design is accrual accounting:

1. Purchase: Dr Inventory Asset or Purchases; Cr Accounts Payable.
2. Supplier payment: Dr Accounts Payable; Cr Cash/Bank.
3. Later dispensing: post COGS and reduce inventory using the existing cost
   snapshot policy.

This was not implemented because the account policy is not configured and
posting now could double-count purchases or payments.

## Remaining verification limits

The in-app browser runtime does not expose viewport emulation or print-preview
inspection controls. Tablet/mobile layouts, mobile modals, and visual print
preview therefore remain unverified. The source includes responsive and print
rules, but source inspection is not a substitute for those runtime checks.

Database audit after fixture cleanup: negative stock 0, negative due 0,
paid-over-final 0, orphan visits 0, orphan labs 0, orphan prescriptions 0,
orphan positive payments 0, duplicate bill adjustments 0, duplicate active lab
bridges 0, and unbalanced journal groups 0.
